A new care pathway combining digital tools and personalized human support is being tested to improve symptom management and autonomy for patients receiving endocrine therapy. The HOPE trial shows an average reduction in symptom burden of 3.41 points among participants in the new pathway, but results fell short of statistical significance.
Gustave Roussy physicians and researchers showcase promising studies on immunotherapy and digital health at the ESMO 2026 Congress, aiming to improve treatment outcomes for cancer patients. The institution's UNLOCK programme and other initiatives are highlighted as key contributors to these advancements.
Gustave Roussy is ranked Europe's leading cancer center and third best worldwide, reflecting its excellence in patient care and innovation. The Institute's unique model integrates care, research, and education to give patients faster access to cancer treatments.
Gustave Roussy and The Lancet launch a landmark international lecture series in oncology, focusing on personalised prevention. Renowned expert Professor Timothy R. Rebbeck will deliver a lecture on tailored cancer prevention strategies.
The Gustave Roussy Prize recognizes outstanding research in oncology, improving patient outcomes and understanding of cancer. Applications are open until August 26, 2026, with a €200,000 award to be presented annually by Fondation Gustave Roussy.
Alexandre Detappe has been awarded an ERC Proof of Concept grant to develop nanoparticles that promote interactions between immune cells and cancer cells, aiming to improve the effectiveness of immunotherapy for solid tumors. The project will provide preclinical validations and prepare its next stages of development.
The Gustave Roussy Prize recognizes scientists whose work improves cancer treatment and patient outcomes. Established by Pierre Fabre Laboratories, the €200,000 award aims to push boundaries of oncology and offer personalized treatments.
A new immunotherapeutic agent has been shown to significantly improve treatment outcomes for children and adolescents with advanced non-Hodgkin lymphoma, particularly Burkitt lymphoma. The agent, rituximab, in combination with chemotherapy, has a cure rate of over 95% and reduces the risk of disease progression by up to 70%.
A new analysis published in Annals of Oncology suggests that hormone therapy has a greater impact on women's quality of life compared to chemotherapy, especially in postmenopausal patients. This finding challenges current international guidelines recommending prolonged hormone therapy for 5-10 years.
Researchers develop radiomic signature to predict efficacy of immunotherapy in patients with solid tumors. The algorithm analyzes CT scan images to extract biological information, providing a predictive score for treatment effectiveness.
A team of international researchers has mapped the family trees of cancer cells in AML to understand its response to enasidenib and how it can be combined with other anti-cancer drugs. The study provides clues about how AML cells become resistant to therapy and may help design future therapy trials.
Researchers identified 'clathrin-coated pits' as a new mechanism involved in cancer cell migration. These structures allow cancer cells to attach to surrounding collagen fibers and move around.